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ABSTRACT 
 
Purpose Clinical decision support systems (CDSS) are promoted as powerful tools to 
improve pharmacotherapy. We aimed to evaluate the potential contribution of CDSS to 
patient management in clinical practice. 
Methods We prospectively analyzed the pharmacotherapy of 100 medical inpatients through 
the parallel use of the CDSS Pharmavista, DrugReax and TheraOpt. After expert discussion 
that also considered all patient-specific clinical information we selected apparently relevant 
alerts, issued according recommendations to physicians and recorded subsequent 
prescription changes. 
Results For 100 patients with a median of eight concomitant drugs Pharmavista, DrugReax 
and TheraOpt generated a total of 53, 362 and 328 interaction alerts, respectively. Among 
those we identified and forwarded 33 clinically relevant alerts that were followed by 19 
according prescription changes. Four adverse drug events were associated with interactions. 
The proportion of clinically relevant alerts among all alerts (positive predictive value) was 5.7, 
8.0 and 7.6%, and the sensitivity to detect all 33 relevant alerts 9.1, 87.9 and 75.8% for 
Pharmavista, DrugReax and TheraOpt, respectively. TheraOpt recommended 31 dose 
adjustments, of which we considered 11 as relevant, and three were followed by dose 
reductions. 
Conclusions CDSS are valuable screening tools for medication errors, but only a small 
fraction of their alerts appear relevant in individual patients. In order to avoid overalerting 
CDSS should use patient-specific information and management-oriented classifications. 
Comprehensive information should be displayed on-demand, whereas a limited number of 
computer-triggered alerts that have management implications in the majority of affected 
patients should be based on locally customized and supported algorithms. 
 
Keywords: Clinical decision support software, dose adjustment, drug interactions 
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INTRODUCTION 
Adverse drug events (ADE) are an important cause of morbidity, mortality and increased 
healthcare costs and therefore a challenging problem for clinical patient care [1-7]. Drug 
interactions and dosing errors leading to ADE are of special interest because they represent 
preventable medication errors that are suitable targets for highly efficient automated 
interventions through computerized physician order entry (CPOE) with clinical decision 
support systems (CDSS). The efficacy of CDSS to affect physicians’ behavior in clinical 
practice and thereby to reduce medication errors and improve monitoring of 
pharmacotherapy has been well established, whereas their efficacy to reduce ADE and costs 
is less well documented and needs further investigation [8-15]. Furthermore, only few studies 
compared the performance of different CDSS, and even those were usually not conducted 
under real-life conditions. Classification and grading of medication errors is a complex and 
challenging task, and previous studies reported major disagreements in the assessment of 
drug interactions between different CDSS [16-18] and specialists [19]. Furthermore, general 
assessments may not well apply to specific patients where prescribing clinicians also use 
additional complex non-standardized clinical information for management decisions [20, 21]. 
Generally, it appears that most CDSS have a high sensitivity to detect drug interactions at 
the cost of low specificity to discriminate those interactions that are clinically relevant. In 
combination with insufficient consideration of patient-specific factors by CDSS this leads to 
indiscriminate overriding of alerts by prescribing clinicians, which jeopardizes the efficacy of 
CDSS to improve medication safety in clinical practice [22]. 
For our routine clinical pharmacology “safety ward rounds” we use several CDSS as an initial 
screening tool to search for drug interactions and dosing errors in hospitalized patients. 
However, given the limitations mentioned above, after automated screening we also access 
the electronic medical records of the respective patients in order to evaluate the clinical 
relevance of potential medication errors initially identified by CDSS. Only if we conclude that 
a potential medication error is clinically relevant in the patients’ individual clinical context, we 
alert the responsible physician and discuss alternatives as appropriate. Because there is a 
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need for systematic evaluations of the performance of different CDSS in real-life clinical 
settings the current study analyzed our experience with the use of different CDSS in 
combination with clinical pharmacology expertise for the identification and prevention of 
medication errors. 
 
 
METHODS 
 
Study design 
We present a prospective naturalistic analysis that evaluated the performance of CDSS used 
as part of our surveillance of pharmacotherapy at two general internal medicine wards of a 
tertiary care university hospital. Our surveillance has the aim to optimize efficacy and safety 
of pharmacotherapy. Because this study is a systematic analysis of our established routine 
clinical practice it was exempt from ethical approval. A summary of the procedures is 
presented in Figure 1. The study includes 100 consecutive patients for an evaluation of all 
concomitantly prescribed drugs with a focus on potential drug interactions. There were no 
formal exclusion criteria. A formal power analysis was not applicable in this descriptive pilot 
analysis, and the decision to include 100 patients was based on pragmatic and somewhat 
arbitrary grounds. As our surveillance is performed at certain days of the week and patients 
may also had been transferred from other wards, the day of analysis in relation to hospital 
admission varied. All concomitantly prescribed drugs were simultaneously analyzed with 
three different CDSS, i.e. Micromedex DRUG-REAX®, Atheso TheraOpt® (which in the 
meantime has been taken over by ID Berlin), and Pharmavista® [23-25]. Of note, 
Pharmavista did not allow the entry of more than eight concomitantly used drugs at a time, 
and for patients using more than eight drugs an interaction analysis could therefore not be 
performed with Pharmavista. Automatically generated alerts from all three CDSS were 
documented. Subsequently at least one junior and one senior clinical pharmacologist from 
our department discussed and evaluated the automatically generated alerts for their clinical 
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relevance in the individual clinical context of each patient. Alerts were defined as clinically 
relevant if we considered a change of therapy as necessary. For that purpose we also 
accessed the hospital’s clinical information system containing all electronic drug 
prescriptions, medical reports and laboratory results. Subsequently we forwarded only 
presumably clinically relevant alerts to the treating physician, usually by personal 
communication during ward rounds or over the phone, plus an entry into the electronic 
patient record. If appropriate we also provided additional information and management 
recommendations including possible alternative therapies and monitoring. Thereafter we 
followed the electronic prescribing record for those patients until hospital discharge in order 
to document whether prescriptions were changed in accordance with our recommendations. 
Furthermore, we also specifically searched medical reports and laboratory results for signs 
and symptoms of ADE that may have resulted from prescriptions addressed in the alerts. 
 
Outcomes and data analysis 
Primary outcomes of the study were the comparative number of alerts generated by each 
CDSS, and the fractions thereof that we considered as clinically relevant and therefore 
forwarded to the treating physicians. In order to compare the performance of the three CDSS 
we calculated their sensitivity and positive predictive value (PPV) regarding the identification 
of clinically relevant drug interactions as follows. Sensitivity = number of interactions among 
all interactions evaluated as clinically relevant identified by the respective CDSS divided by 
all interactions evaluated as clinically relevant identified by any CDSS or during expert 
discussion; PPV = number of interactions identified by the respective CDSS and evaluated 
as clinically relevant divided by the number of interactions identified by the respective CDSS. 
We compared the sensitivity and PPV between different CDSS using the chi square test. 
Additional measures of interest included the number of actual medication changes in 
response to those alerts that we had forwarded to the treating physicians, as well as stratified 
analyses, e.g. by CDSS grading, and description of specific alerts and associated ADE. Data 
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management, analyses and figures were done using STATA 11.2 for MacOS X (STATA 
corporation, College Station, TX, USA). 
 
 
RESULTS 
 
Patient characteristics and drug use 
Demographic and clinical characteristics of all 100 included patients are presented in Table 
1. The median age was 59.3 years (range 23 - 86), and in 70 patients the pharmacotherapy 
was analyzed between days 2 and 9 after admission (median and mean 5 and 6.5 days, 
respectively). Forty-four patients had impaired renal function with a glomerular filtration rate 
(GFR) below 60 ml/min, 11 had liver disease with a CHILD score ≥7, 23 had undergone 
organ transplantation at any time in the past, and 25 patients had malignant tumors. 
Table 2 presents the most commonly prescribed drugs in the study population. Overall there 
were 892 prescriptions in 100 patients. Based on the presented classification antibiotics 
ranked as the most frequently prescribed drug class accounting for 110 prescriptions (12.3%) 
in 50 patients, followed by heparins, proton pump inhibitors, diuretics and beta-blockers. 
A histogram of the polypharmacy distribution is shown in Figure 2. The mean and median 
number of concomitant substances prescribed to each patient was 8.9 and 8, respectively. 
 
Drug interactions 
The correlation between polypharmacy and the mean number of identified interactions per 
patient by each CDSS is shown in Figure 3. As expected based on the exponential increase 
of possible combinations, increasing polypharmacy was also associated with a pronounced 
increase of identified interactions. Because Pharmavista could only analyze up to eight 
concomitantly prescribed drugs, there are no results from Pharmavista for patients receiving 
more than eight drugs. Consequently the overall number of interactions identified by 
Pharmavista was much lower compared to DrugReax or Theraopt (Pharmavista 53, 
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DrugReax 362, TheraOpt 328). As expected, for patients receiving up to eight drugs 
differences in the number of identified interactions were smaller (Pharmavista 53, DrugReax 
75, TheraOpt 56). An overview of the identification of drug interactions by each CDSS 
including our subsequent expert evaluation and implementation of the resulting 
recommendations by the treating physicians is provided in Table 3. Among all interaction 
alerts generated by any CDSS we evaluated 33 interactions as clinically relevant in the 
individual clinical context of the respective patients. Of note, when a CDSS classified an alert 
as severe and we did not forward this alert to the treating physician, the reason for our 
decision was documented. For example, there were five “severe” pharmacokinetic interaction 
alerts with cyclosporine, but therapeutic drug monitoring indicated appropriate dose 
adjustment with concentrations in the therapeutic range. Other examples include the 
combination of several drugs that increase the risk of bleeding when there was an evidence-
based indication for this combination, or the combination of several potassium sparing drugs 
when potassium concentrations were indeed normal and stable. The proportion of generated 
alerts that we considered as clinically relevant (which corresponds to the PPV) was 
comparable for the three CDSS, i.e. between 5.7 and 8% (p >0.1 for all comparisons). The 
sensitivity to detect the 33 relevant interactions was 87.9% for DrugReax, 75.8% for 
TheraOpt, and 9.1% for Pharmavista (p <0.001 for TheraOpt or DrugReax vs. Pharmavista; 
p>0.1 for DrugReax vs. TheraOpt). Further stratification by severity classification (Table 3) 
showed a poor correlation between CDSS severity class and our evaluation of clinical 
significance for individual patients, and that DrugReax assigned a higher proportion of its 
alerts to a higher severity class than TheraOpt. A detailed description of all relevant 
interactions is presented in Table 4. Amiodarone was involved in eight interactions, 
antimycotics in seven, and statins and immunosuppressants in six each. Pharmacokinetic 
and pharmacodynamic interaction mechanisms were involved with an about equal frequency. 
For 19 of the 33 forwarded alerts (57.6%) we observed a subsequent prescription change 
that was in line with our recommendations. 
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Dosing 
TheraOpt is also able to identify dosing errors based on recommended maximum doses for 
specific indications, gender, age, and renal and liver function. We used this feature for an 
evaluation of appropriate dosing for all prescriptions. TheraOpt recommended 31 dose 
adjustments, and we found one additional dosing problem related to decreased first pass of 
metoprolol in cirrhosis. Among those we considered 11 as justified and forwarded 
recommendations for prescription changes, which were followed by according changes in 
three cases (Table 5). 
 
Adverse drug events 
In four patients we detected adverse events that were possibly related to the identified 
interaction or dosing issues. In the first case oral ciprofloxacin was combined with oral 
calcium, and the patient developed cholecystitis and E. coli sepsis. Impaired absorption of 
ciprofloxacin may have contributed to treatment failure, leading to prolonged hospitalization 
in this case. In the second case a patient developed hypokalemia (2.9 mmol/l) under 
combined therapy with hydrochlorothiazide, torasemide and prednisone. After medication 
change the patient’s serum potassium quickly normalized. The third patient concomitantly 
received itraconazole capsules and pantoprazole. Proton pump inhibitors are known to 
impair the bioavailability of itraconazole capsules [26], and drug monitoring indeed showed 
subtherapeutic itraconazole concentrations (0.2 mg/l, target level is above 1). The fourth 
patient had a transjugular intrahepatic portosystemic shunt (TIPS) and received 6 mg 
budesonide per day for autoimmune hepatitis with cirrhosis stage Child B. This patient 
developed a thrombosis of the TIPS. Elevated bioavailability of budesonide due to portocaval 
shunting in association with portal vein thrombosis has been described [27], and elevated 
concentrations may have contributed to TIPS thrombosis here. 
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DISCUSSION 
This study presents a systematic analysis of our experience with three different CDSS used 
as screening tools for medication errors in daily clinical routine. 
First, our results provide information on the occurrence of specific medication errors in the 
studied setting. Amiodarone, antimycotics, cholesterol lowering HMG-CoA-reductase 
inhibitors and immunosuppressants were most frequently involved in relevant interactions, 
underlining that any prescribing physician should give particular attention to their interaction 
profiles and routinely check for interactions when prescribing these drugs. Of interest, a 
previous study using a different CDSS in a different population of 84,607 psychiatric 
inpatients also found amiodarone to have the highest intrinsic risk of interactions [28]. We 
also we found some cases with a need for dose-adjustments. Most were related to renal 
insufficiency and some also to cirrhosis and high age, but there was no single drug frequently 
prescribed with an unadjusted dose. Overall, a total of 22 medication changes following our 
combined 44 recommendations relating to interactions or dosing in 100 patients suggest that 
pharmacotherapy could be improved in a considerable proportion and absolute number of 
hospitalized patients. And although our analysis was not designed and powered to 
demonstrate a reduction in clinical outcomes and costs, the detection of possible ADE in 4% 
of the population is in accordance with earlier reports [1-4]. Although relatively rare, an 
extrapolation to the whole patient population of a hospital would yield a considerable 
absolute number of preventable ADE and therefore supports the view that local efforts to 
introduce preventive countermeasures should be increased. 
Considering CDSS as such potentially appropriate countermeasures, the results of our study 
provide important insight into several areas of interest, i.e. the comparative performance, the 
applicability, and the clinical relevance and potential benefits of CDSS use in routine clinical 
practice. In contrast to the primarily intended use of CDSS by prescribers and office 
pharmacists, a key feature of our study is that we as clinical pharmacologists used CDSS as 
a screening tool for medication errors, whereas the prescribing physicians were not directly 
confronted with CDSS-generated alerts. Instead, we made a preselection of presumably 
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clinically relevant alerts where we also used patient-specific information and our clinical 
expertise, and subsequently also enhanced the automated alerts by additional management 
recommendations. The rationale for this approach is our own experience as well as an 
increasing number of reports in the literature [22, 29-34] that identified overalerting as a 
major issue with currently available CDSS. Indeed, although most alerts could be considered 
as generally valid, for all three CDSS that we used more than 90% of alerts appeared 
clinically irrelevant when they were applied to the management of specific patients. 
Therefore, also in our setting forwarding all alerts without selection would have most likely 
led to indiscriminate overriding. Furthermore, our finding that many clinically relevant 
interactions were classified as moderate or even mild according to the classic “traffic light” 
grading used by all three CDSS indicates that even filtering only “severe” alerts would not be 
a reasonable solution. Indeed, a previous study also reported that customization of CDSS by 
common severity levels was not able to improve effectiveness [32]. The more management-
oriented Operational Classification of Drug Interactions (ORCA) has been developed with 
this issue in mind [35], and recently we proposed an extension of ORCA that also supports 
the implementation of patient-specific information and potential outcomes of drug interactions 
in CDSS algorithms [28, 36, 37]. Currently ongoing studies that evaluate CDSS based on 
such management-oriented classifications will show whether they can make a relevant 
contribution to the reduction of overalerting. 
Comparing the three CDSS for their sensitivity to detect clinically relevant interactions, 
DrugReax and TheraOpt performed better than Pharmavista. This result must certainly be 
interpreted in consideration of Pharmavista’s inability to analyze more than eight drugs 
concomitantly, which applied to 42% of our medical inpatient population, and it may be less 
of an issue in a pharmacy setting, where Pharmavista is frequently used. Nevertheless, our 
results indicate that it is quite a relevant limitation for a medical inpatient population. 
Among all interaction alerts that we considered as relevant 58% were actually followed by 
according prescription changes. This demonstrates that our preselection based on patient-
specific clinical information and adding of management recommendations in combination 
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with personal communication of the alerts were generally well-received and able to overcome 
the major problem of overriding of alerts to a large part. For the remaining 42% of alerts that 
were not followed by a prescription change, clinicians may have either judged our 
recommendations as not justified (which may or may not be true), or indiscriminative 
overriding may have occurred. Previous studies named the most frequent reasons for alert 
overriding: the problem was already known but clinically not important, there were no 
reasonable alternatives while the benefit was considered to be greater than the risk, the 
potential problem could be managed by appropriate monitoring, the dose had been adjusted, 
or the patient had previously tolerated the medication [31, 32]. Similar reasons were brought 
forward when we contacted the prescribers. Furthermore, we realize some inevitable 
limitations of our assessments, i.e. in the absence of a gold standard for the clinical 
relevance of potential medication errors it is possible that we excluded some relevant alerts, 
oversaw additional medication errors, or on the other hand forwarded some irrelevant alerts. 
However, neither did we identify additional ADE, nor does it appear likely that the combined 
sensitivity of the three CDSS plus our manual review failed to identify a relevant number of 
medication errors. 
Regardless of the reason for overriding and the differences that we found between CDSS, 
the fact that less than 10% of automated alerts were assessed as relevant for individual 
patients forces us to rethink how future CDSS can be effective and efficient for the 
prevention of medications errors, ADE and unnecessary costs in clinical practice. Maximum 
sensitivity may be a common priority in the development of CDSS, and much of their content 
can be tracked down to the safety information in the manufacturer’s prescribing information, 
where, also for legal reasons, comprehensiveness rather than clinical relevance is 
determinative. The comprehensive and generally valid alerts and comments from all three 
CDSS were certainly useful for screening and learning purposes in our setting. However, 
eventually CDSS must be integrated with CPOE and automatically display alerts that have a 
high propensity of clinical relevance. Indeed, approaches that target specific relevant 
problems of pharmacotherapy have demonstrated their efficacy not only to change 
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prescribing behavior but also to improve clinical outcomes [38]. Therefore, we propose that 
on the one hand the valuable comprehensive knowledge from CDSS should be easily 
available (via “one click”) to the prescriber, but only on an on-demand basis. On the other 
hand, there should be a list with a limited number of automatically computer-triggered alerts. 
Clinical pharmacologists can initially develop such a list and make a preselection that 
focuses on clinical relevance and management implications. Also local retrospective 
systematic evaluations of medication errors and adverse drug events that occurred in the 
past can contribute to and help to justify the use of such a list [36, 37]. But the list should also 
be reviewed and supported by local leading clinicians in order to enhance its local 
acceptance. Furthermore, the importance of patient-specific factors suggests that alert 
algorithms must also include as much laboratory and clinical information as possible. Indeed, 
obtaining laboratory results as part of intensified monitoring could also be part of clinical 
actions recommended and surveyed by CDSS. This requires interfaces that integrate CDSS 
with laboratory and clinical information systems. For example, alert algorithms may include 
current electrolyte results and QTc times from automated ECG readings. Although we did not 
use CDSS with integration into CPOE and clinical information systems in our setting, it is 
important to note that TheraOpt and other currently available CDSS have indeed been 
designed in such a way. However, if this approach is used for all interactions of a highly 
sensitive CDSS, its complexity and applicability will likely become uncontrollable and result 
once more in overriding. 
 
 
CONCLUSIONS 
The studied CDSS are valuable screening tools for medication errors, but only a small 
fraction of all alerts are clinically relevant in individual patients. Insufficient use of patient-
specific information in alert algorithms and lack of local customization compromise their 
applicability and efficacy in clinical practice. In addition, lack of scientific evidence in complex 
individual patient care and common off-label use remain major challenges for CDSS. We 
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therefore propose that CDSS should separate comprehensive on-demand information from 
selected computer-triggered alerts that must be locally supported, customized and frequently 
updated, and have management implications in the majority of patients where they are 
displayed. The initial setup plus necessary ongoing evaluations and adjustments of such a 
system requires expertise and additional resources. However, compared to a standard 
CDSS without appropriate local promotion and support, such an approach may not only be 
more efficacious but also more efficient. 
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FIGURE LEGENDS AND TABLES  
  
 
 
 
FIGURE LEGENDS 
 
 
Figure 1 - Procedures 
Overview of the pharmacotherapy evaluation process.  
 
 
Figure 2 - Polypharmacy 
Histogram of the polypharmacy distribution for 100 patients. 
 
 
Figure 3 - Polypharmacy and identification of drug interactions by CDSS 
Mean number of identified interactions per patient for each CDSS over polypharmacy 
categories in 100 patients. Pharmavista did not allow analysis of more than 8 concomitant 
drugs. 
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TABLES 
 
Table 1 - Patient characteristics 
 
 
1 Only one primary diagnosis per patient 
2 Most recent glomerular filtration rate (GFR) before pharmacotherapy evaluation according to the MDRD-formula  
Characteristics n 
  
Total 100 
  
Sex  
    Female 42 
    Male 58 
  
Age category (years)  
    <50 20 
    50-59 32 
    60-69 19 
    70-79 17 
    ≥80 12 
  
Time of pharmacotherapy evaluation (days after admission)  
    0-1 16 
    2-4 33 
    5-9 37 
    ≥10 14 
  
Disease categories1  
   Gastroenterology and Hepatology 25 
   Nephrology 24 
   Internal medicine 17 
   Cardiology 11 
   Angiology 6 
   Oncology 4 
   Pneumology 4 
   Endocrinology 3 
   Hematology 3 
   Infectiology 2 
   Immunology 1 
  
Renal function (GFR, ml/min/1.73m2)2  
    ≥60 56 
    30-59 22 
    <30, no dialysis 11 
   Dialysis 11 
  
Liver disease with CHILD score ≥7  
   Yes 11 
   No 89 
  
Malignancy  
   Yes 25 
   No 75 
  
Transplantation  
   Liver 2 
   Lung 5 
   Kidney 16 
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Table 2 - Prescription frequencies for different drug categories 
Number of prescriptions and number of patients with such prescriptions for different drug categories 
 
Drug classes 
Number of prescriptions Number of patients with 
prescriptions 
 n % n (=%) 
Total 892 100 100 
    
Antibiotics 110 12.3 50 
Heparins 63 7.1 63 
Proton pump inhibitors 60 6.7 60 
Diuretics 52 5.8 40 
Beta blockers 43 4.8 43 
Immunosuppressants 40 4.5 23 
HMG-CoA inhibitors 38 4.3 38 
Antiplatelets 37 4.2 28 
Corticosteroids systemic 34 3.8 34 
ACE inhibitors 28 3.1 28 
Vitamins 28 3.1 28 
Antivirals 26 2.9 15 
Calcium salts 22 2.5 22 
Laxatives 22 2.5 18 
Hormones 20 2.2 17 
Calcium channel blockers 19 2.1 19 
Antifungals 16 1.8 12 
Potassium salts 16 1.8 16 
Angiotensin renin blockers 14 1.6 14 
Benzodiazepines and GABA agonists 14 1.6 13 
Oral anticoagulants 14 1.6 14 
Insulins 13 1.5 9 
Analgetics metamizole 11 1.2 11 
Analgetics opioids 10 1.1 10 
Analgetics paracetamol 9 1.0 9 
Antidepressants 9 1.0 7 
Antiemetics 9 1.0 8 
Antiepileptics 9 1.0 7 
Oral glucose lowering agents 9 1.0 7 
Antiarrhythmics 8 0.9 7 
Antiasthmatics 7 0.8 3 
Magnesium salts 7 0.8 7 
Neuroleptics 7 0.8 7 
Antiparkinson drugs 4 0.5 2 
Uricostatics 4 0.5 4 
NSAIDs 2 0.2 2 
    
Other 58 6.5 44 
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Table 3 - Identification and evaluation of drug interactions 
Identification of drug interactions by CDSS, further expert evaluation, according prescription changes 
and associated adverse events. First overall results are presented, followed by stratifications over 
severity grading of interactions.   
 
Identification and evaluation of interactions PharmaVista1 DrugReax TheraOpt 
 n % n % n % 
All interactions 53 100 362 100 328 100 
  Evaluated as clinically relevant (PPV2) 3 5.7 29 8.0 25 7.6 
  Sensitivity3  9.1  87.9  75.8 
  Alert followed by prescription change 3 5.7 17 4.7 13 4.0 
  Adverse event associated with interaction 0 0 3 0.8 3 0.9 
       
Mild interactions 36 100 23 100 213 100 
  Evaluated as clinically relevant (PPV2) 3 8.3 0 0 4 1.9 
  Sensitivity3  9.1  0  12.1 
  Alert followed by prescription change 3 8.3 - - 4 1.9 
  Adverse event associated with interaction 0 0 - - 0 0 
       
Moderate interactions 17 100 248 100 104 100 
  Evaluated as clinically relevant (PPV2) 0 0 12 4.8 15 14.4 
  Sensitivity3  0  36.4  42.4 
  Alert followed by prescription change - - 5 2.0 5 4.8 
  Adverse event associated with interaction - - 3 1.2 3 2.9 
       
Severe interactions 0 - 91 100 11 100 
  Evaluated as clinically relevant (PPV2) - - 17 18.7 6 54.5 
  Sensitivity3  0  51.5  18.2 
  Alert followed by prescription change - - 12 13.2 4 36.4 
  Adverse event associated with interaction - - 0 0 0 0 
       
 
1Pharmavista did not analyze pharmacotherapy if n concomitant drugs was >8 
2Percentage value equals positive predictive value (PPV): PPV = n interactions identified by the respective CDSS 
and evaluated as clinically relevant / n interactions identified by the respective CDSS * 100. 
3Sensitivity (%) = n interactions among all 33 interactions evaluated as clinically relevant identified by the 
respective CDSS / all 33 interactions identified by any source and evaluated as clinically relevant * 100 
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Table 4: Listing of all drug interactions that were identified by CDSS and evaluated as clinically 
relevant during expert discussion (29 distinct interactions occurring in 33 instances) 
Interacting drugs CDSS detection and 
severity grading1 
Potential adverse event Mech-
anism2 
Rx 
change 
 PhVis DRx ThOpt    
Amiodarone - simvastatin x 3 2 Myopathy PK No 
Amiodarone - atorvastatin x 2 2 Myopathy PK Yes 
Amiodarone - metronidazole x 3 x QT-prolongation PD Yes 
Amiodarone - cotrimoxazole x 3 3 QT-prolongation PD Yes 
Amiodarone - itraconazole x 3 x QT-prolongation PD Yes 
Amiodarone - clarithromycin (n=2)  x 3 3 QT-prolongation PD 2xYes 
Amiodarone - ciprofloxacin  x 3 x QT-prolongation PD Yes 
Cyclosporine - simvastatin x 3 2 Myopathy PK Yes 
Cyclosporine - pravastatin x 2 2 Myopathy PK No 
Cyclosporine - morphine - 
loperamide  
x x x Increased levels of cyclosporine 
and morphine 
PK No 
Tacrolimus - itraconazole x 3 2 Increased levels of tacrolimus PK No 
Tacrolimus - clarithromycin x 2 2 Increased levels of both drugs PK No 
Tacrolimus - metronidazol x 2 x Increased levels of tacrolimus PK No 
Clarithromycin - domperidone - 
itraconazol 
x x 2 QT-prolongation PK Yes 
Clarithromycin - cotrimoxazole 
(n=3) 
x 3 3 QT-prolongation PD 1x Yes, 
2x No 
Cotrimoxazole - fluconazole x 3 x QT-prolongation PD 1 
Ciprofloxacin - atorvastatin x 2 2 Myopathy PK No 
Ciprofloxacin - calcium3 (n=2) x 2 2 Decreased efficacy (BV4 ↓) PK Yes / No 
Itraconazole - ranitidine x 2 2 Decreased efficacy (BV4 ↓) PK No 
Itraconazole - omeprazole x 2 2 Decreased efficacy (BV4 ↓) PK No 
Itraconazole - pantoprazole3 x 2 2 Decreased efficacy (BV4 ↓) PK No 
Pipamperone - trimipramine x 3 2 QT-prolongation PD No 
Ursodeoxycholic acid - 
colestyramin 
1 x 1 Decreased efficacy (BV4 ↓) PK Yes 
Daptomycin - pravastatin x x 2 Myopathy PD Yes 
Torasemide - HCTZ - prednisone3 x 2 1 Hypokalemia PD Yes 
Ginkgo biloba - acetylsalicylic acid 1 3 1 Bleeding PD Yes 
Ginkgo biloba - clopidogrel 1 2 1 Bleeding PD Yes 
Clopidogrel - esomeprazole x 3 x Decreased clopidogrel efficacy PK Yes 
Terlipressin - quetiapine x 3 x QT-prolongation PD Yes 
 
1 Key for severity grading: 1 = mild, 2 = moderate, 3 = severe, x = not detected; PhVis = Pharmavista, 
DRx = DrugReax, ThOpt = Theraopt. 
2 PK = pharmacokinetic, PD = pharmacodynamic. 
3 Associated with adverse event (see text). 
4 BV = bioavailability, refers to the first drug of the listed combination 
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Table 5: Dosing recommendations initially identified by TheraOpt that we evaluated as clinically 
relevant. 
 
Actual prescription1 Dosing issue Prescription 
change 
Zolpidem 10 mg >65 yrs standard dose 5 mg Yes / No 
Chlortalidon Contraindicated in severe renal impairment Yes 
Budesonid2 In cirrhosis high first pass Yes 
Hydrochlorothiazide Contraindicated in severe renal impairment No 
Metformin Contraindicated in severe renal impairment No 
Simvastatin 40 mg Max. 10mg if GFR3<30 No 
Metamizol 3 g Lower dose in renal impairment No 
Pantoprazol 40 mg In cirrhosis max. 20 mg No 
Clarithromycin 2x250 mg Max. 250 mg if GFR3<30  No 
 
1 n=1 for all dosing errors with the exception of zolpidem 10 mg (n=2) 
2 Associated with adverse event (see text) 
3 GFR = glomerular filtration rate 
 
